ARTICLE | Clinical News
Adare’s APT-1011 meets in Phase IIb for eosinophilic esophagitis
March 14, 2019 7:41 PM UTC
Adare said it plans to start a Phase III program next half of APT-1011 (AdvaTab Fluticasone) to treat eosinophilic esophagitis after reporting that the product met the primary endpoint in the Phase IIb FLUTE trial in the indication. APT-1011 is an orally disintegrating tablet formulation of the corticosteroid fluticasone propionate that uses the company's AdvaTab technology.
There are no FDA-approved therapies for eosinophilic esophagitis, according to Adare Pharmaceuticals Inc. (Lawrenceville, N.J.)...
BCIQ Company Profiles